e-learning
resources
Barcelona 2013
Wednesday, 11.09.2013
Emerging new targets for the treatment of respiratory diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The role of soluble guanylyl cyclase in chronic obstructive pulmonary disease
L. Dupont, C. Glynos, T. Vassilakopoulos, A. Papapetropoulos, P. Brouckaert, A. Giannis, G. Joos, K. Bracke, G. Brusselle (Ghent, Belgium; Athens, Patras, Greece; Leipzig, Germany)
Source:
Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases
Session:
Emerging new targets for the treatment of respiratory diseases
Session type:
Oral Presentation
Number:
4860
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
L. Dupont, C. Glynos, T. Vassilakopoulos, A. Papapetropoulos, P. Brouckaert, A. Giannis, G. Joos, K. Bracke, G. Brusselle (Ghent, Belgium; Athens, Patras, Greece; Leipzig, Germany). The role of soluble guanylyl cyclase in chronic obstructive pulmonary disease. Eur Respir J 2013; 42: Suppl. 57, 4860
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Related content which might interest you:
The role of guanylyl cyclase in resistive breathing
Source: Annual Congress 2013 –Experimental models in critical care
Year: 2013
Fractional exhaled nitric oxide in chronic obstructive pulmonary disease
Source: International Congress 2015 – Exhaled biomarkers in monitoring airways disease
Year: 2015
The cycle of the nitric oxide metabolism in patients with COPD and chronic cerebrovascular diseases (CCVD)
Source: Annual Congress 2013 –The vulnerable patient and ageing cells
Year: 2013
The role of inducible NO synthase (iNOS) in a cell model of steroid resistance in chronic obstructive pulmonary disease
Source: Annual Congress 2008 - Basic science in asthma and COPD
Year: 2008
Use of different exhaled nitric oxide multiple flow rate models in COPD
Source: Eur Respir J 2007; 29: 651-659
Year: 2007
Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension
Source: Eur Respir J 2008; 32: 881-891
Year: 2008
Exhaled nitric oxide in respiratory diseases other than asthma
Source: Eur Respir Monogr 2010; 49: 45-55
Year: 2010
Nitric oxide in the COPD pathogenesis in patients with pulmonary tuberculosis
Source: International Congress 2019 – Oxidative stress, hypoxia and microbial exposure in the pathogenesis of pulmonary disease
Year: 2019
Exhaled nitric oxide in chronic obstructive pulmonary disease: relationship to pulmonary function
Source: Eur Respir J 2001; 17: 934-938
Year: 2001
Asymmetric dimethylarginine contributes to airway nitric oxide deficiency in patients with COPD
Source: International Congress 2015 – Exhaled biomarkers in monitoring airways disease
Year: 2015
Evaluation of exhaled nitric oxide in idiopathic interstitial lung diseases
Source: International Congress 2015 – IIPs: orphan
Year: 2015
Is arginase a potential drug target in tobacco-induced pulmonary endothelial dysfunction?
Source: International Congress 2015 – Pulmonary hypertension: promising small molecules
Year: 2015
Fractional exhaled nitric oxide in patients with chronic obstructive pulmonary disease
Source: International Congress 2019 – FeNO in airway diseases and asthma-COPD overlap identification
Year: 2019
Differential assessment of airway inflammation in chronic obstructive pulmonary disease (COPD) by measurements of exhaled nitric oxide (NO) derived from peripheral
vs.
central airways
Source: Eur Respir J 2003; 22: Suppl. 45, 279s
Year: 2003
Xanthine oxidase inhibition reduces reactive nitrogen species production in COPD airways
Source: Eur Respir J 2003; 22: 457-461
Year: 2003
Nitric oxide modulates vascular remodelling in a model of chronic allergic lung inflammation
Source: Eur Respir J 2006; 28: Suppl. 50, 432s
Year: 2006
Role of nitric oxide pathway in pathogenesis of high altitude pulmonary hypertension
Source: Eur Respir J 2007; 30: Suppl. 51, 551s
Year: 2007
Gene polymorphisms of endothelial nitric oxide synthase in pulmonary arterial hypertension
Source: Annual Congress 2005 - Pulmonary hypertension: pathophysiology
Year: 2005
Severity of scleroderma lung disease is related to alveolar concentration of nitric oxide
Source: Eur Respir J 2007; 30: 26-30
Year: 2007
Role of fractional exhaled nitric oxide(FeNO) in obstructive airway diseases in Indian population
Source: International Congress 2015 – Exhaled biomarkers in monitoring airways disease
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept